Gastric Cancer (PD-L1 Expression): Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 55-year-old male with 2 months’ history of shortness of breath, lethargy, and anemia with a 6kg weight loss. His hypertension is well controlled on losartan. He has no other co-morbidities and no relevant family history. He is a non-smoker and his alcohol intake is 6 drinks per week. He had a 19-year-old daughter who died from acute lymphocytic leukemia 4 years ago. An upper gastrointestinal endoscopy showed a 6 cm ulcer in the gastric fungus and biopsy showed poorly differentiated intestinal type adenocarcinoma, HER2 negative. CT scans revealed a T4N1M2 gastric adenocarcinoma with coeliac axis and retroperitoneal lymphadenopathy.

Originally posted on a forum in the ASCO Connection, users now have the opportunity to claim CME, completion, or participation certificates for completing this activity.

Learning Objectives
- Evaluate the data for immune checkpoint inhibitors for patients with advanced gastric cancer
- Analyze the predictive factors that have been researched regarding response to immune checkpoint inhibitors
- Discuss available PD-1/PD-L1 inhibitors and their safety profiles including the most common immune-related adverse events

Competencies Addressed

  • Medical Knowledge (ACGME, AAPA)
  • Health Promotion, Health Protection, Disease Prevention, and Treatment (ONS)

Target Audience
This course is designed for members of the cancer care team including medical, radiation and surgical oncologists, pathologists, and oncology fellows.